December 31st point prevalent counts by modality figure 3.1

Slides:



Advertisements
Similar presentations
Chapter 7: Pediatric ESRD 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Advertisements

Chapter 4: Hospitalization 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Vol 2, ESRD, Ch ANNUAL DATA REPORT VOLUME 2: END-STAGE RENAL DISEASE Chapter 9: Costs of ESRD.
Vol 2 Figure 1.1 Trends in the number of incident cases of ESRD, in thousands, by modality, in the U.S. population, Data Source: Reference.
Chapter 5: Mortality 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.
UKRR Annual Informatics Meeting, September 2013 Highlights from the 15 th Annual Report Rishi Pruthi Research Fellow UK Renal Registry.
Number of Dialysis and Transplant Units by Year, Number of Units Total Dialysis Only Transplant USRDS 1999 XI-1 Year.
UK Renal Registry 17th Annual Report Figure 1.1. RRT incidence rates in the countries of the UK 1990–2013.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 6: Mortality.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 11: Costs of ESRD.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 10: Dialysis Providers.
USRDS 1999 Point Prevalence Counts by Modality, Data Source, and Year, Count (1000s) Year Center Hemo Functioning Transplant PD Home Hemo Facility.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 5: Hospitalization.
Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.
ESRD Prognoses James Heaf. This Power Point presentation belongs to the Danish Renal Registry, which owns the copyright. It can be freely used.
USRDS USRDS 2002 adr Period prevalent ESRD patient, deaths, & ESRD expenditures figure 12.1.
USRDS 2000 ADR USRDS Hepatitis B vaccine & antibody among patients & unit staff figure 9.1, dialysis patients, 1997, by network.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
USRDS 2000 ADR USRDS Cadaveric donations by gender & race figure 7.1, patients aged
2016 Annual Data Report, Vol 2, ESRD, Ch 5
2016 Annual Data Report, Vol 2, ESRD, Ch 8
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
UK Renal Registry 13th Annual Report
Figure 11.1 Trends in ESRD expenditures,
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Healthy People 2010 targets & levels achieved in 2000 figure hp.1
Figure 10.1 Dialysis unit counts, by unit affiliation, 2011–2014
First-year death rates by modality figure 8
Odd ratio of developing kidney failure figure 1
Patient populations by study group figure 10
Mortality rates in incident ESRD patients figure 9
Volume 2: End-Stage Renal Disease
Summary of the 2013 ERA-EDTA Registry Annual Report
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Chapter 7: ESRD among Children, Adolescents, and Young Adults
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
UK Renal Registry 16th Annual Report
UK Renal Registry 18th Annual Report
2016 Annual Data Report, Vol 2, ESRD, Ch 4
Hospital admissions per patient, by modality figure 5
UK Renal Registry 9th Annual Report 2006
Chapter 9: Healthcare Expenditures for Persons with ESRD
Chapter 2: Clinical Indicators and Preventive Care
CHAPTER 5 Paediatric Renal Replacement Therapy
Volume 2: End-Stage Renal Disease Chapter 4: Hospitalization
Table 4.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, all dialysis patients
Hemoglobin, EPO, & Iron dose figure 4
Volume 2: End-Stage Renal Disease Chapter 6: Transplantation
North west Regional Day
Volume 2: End-Stage Renal Disease
Volume 2: End-Stage Renal Disease
Number of dialysis & transplant units figure 10.1
Volume 64, Pages S3-S12 (December 2003)
Chapter 9: Healthcare Expenditures for Persons with ESRD
CHAPTER 1 All Renal Replacement Therapy In Malaysia
UK Renal Registry 16th Annual Report
UK Renal Registry 14th Annual Report
New ESRD Patients and Main Sources
Cause Specific Death Rates for All Dialysis Patients
Reported ESRD Period and Point Prevalence,
UK Renal Registry 15th Annual Report
UK Renal Registry 14th Annual Report
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
The Use of Vaccines in Adult Patients With Renal Disease
Renal replacement therapy in Latin America
Worldwide incidence of ESRD figure 12.1, per million population
Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary 
Presentation transcript:

December 31st point prevalent counts by modality figure 3.1 USRDS

Number of dialysis patients figure 3.2, projected to 2010 USRDS

Number of transplant patients & patients on the transplant waiting list figure 3.3, projected to 2010 USRDS

Modality at initiation, one year, & two years figure 3 Modality at initiation, one year, & two years figure 3.4, incident patients USRDS

December 31st point prevalence: Hemodialysis, 1990 figure 3 December 31st point prevalence: Hemodialysis, 1990 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Hemodialysis, 1994 figure 3 December 31st point prevalence: Hemodialysis, 1994 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Hemodialysis, 1998 figure 3 December 31st point prevalence: Hemodialysis, 1998 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Hemodialysis, percent change 1990-1998 figure 3.5 USRDS

December 31st point prevalence: Peritoneal dialysis, 1990 figure 3 December 31st point prevalence: Peritoneal dialysis, 1990 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Peritoneal dialysis, 1994 figure 3 December 31st point prevalence: Peritoneal dialysis, 1994 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Peritoneal dialysis, 1998 figure 3 December 31st point prevalence: Peritoneal dialysis, 1998 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Peritoneal dialysis, percent change 1990-1998 figure 3.5 USRDS

December 31st point prevalence: Transplant, 1990 figure 3 December 31st point prevalence: Transplant, 1990 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Transplant, 1994 figure 3 December 31st point prevalence: Transplant, 1994 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Transplant, 1998 figure 3 December 31st point prevalence: Transplant, 1998 figure 3.5, percent of total patients Percent of total patients USRDS

December 31st point prevalence: Transplant, percent change 1990-1998 figure 3.5 USRDS

Modality by age group & gender figure 3 Modality by age group & gender figure 3.6, point prevalent patients on December 31st, 1998 USRDS

Modality by race & gender figure 3 Modality by race & gender figure 3.6, point prevalent patients on December 31st, 1998 USRDS

Modality by primary diagnosis & gender figure 3 Modality by primary diagnosis & gender figure 3.6, December 31st point prevalent patients, 1998 USRDS

Modality at two years after first ESRD service, by age group figure 3 Modality at two years after first ESRD service, by age group figure 3.7, incident patients, 1994-1998 USRDS

Percent distribution of patients by modality, age group, gender, race, & primary diagnosis table 3.1, December 31st point prevalent patients, 1998 USRDS

Percent distribution of patients by treatment modality & network table 3.2, December 31st point prevalent patients, 1996-1998 USRDS

Percent of ESRD patients, by modality & ESRD duration figure 3 Percent of ESRD patients, by modality & ESRD duration figure 3.8, December 31st point prevalent patients, 1998 USRDS

Median age & modality figure 3 Median age & modality figure 3.9, December 31st point prevalent patients, 1998 USRDS